semaglutide clinical trial and Cardiovascular Outcomes in Obesity without Diabetes Oral semaglutide versus subcutaneous liraglutide

The current study showed that the administration of L-carnitine alone is effective in improving fatty liver, and that concomitant administration of L-carnitine and EPA elevates this effectiveness

These symptoms are usually temporary and improve within weeks

2024 Apr 1;30(2):131-141

[2] [5] The most commonly reported side effects of tirzepatide are gastrointestinal in nature, occurring in a substantial proportion of patients during clinical trials

The candidates that exist in 2026 are: clinician judgment (the gold standard, but in short supply), expanded laboratory work (DEXA for body composition, CGM for glycemic patterns, metabolic panels of increasing sophistication), patient-reported priorities (the founder who tells you he cares about muscle is providing useful prior information), and, increasingly, genetics

Published February 2026